Immunotherapy targets in pediatric cancer

Rimas J. Orentas, Daniel W. Lee, Crystal Mackall

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy for cancer has shown increasing success and there is ample evidence to expect that progress gleaned in immune targeting of adult cancers can be translated to pediatric oncology. This manuscript reviews principles that guide selection of targets for immunotherapy of cancer, emphasizing the similarities and distinctions between oncogene-inhibition targets and immune targets. It follows with a detailed review of molecules expressed by pediatric tumors that are already under study as immune targets or are good candidates for future studies of immune targeting. Distinctions are made between cell surface antigens that can be targeted in an MHC independent manner using antibodies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which must be targeted with MHC restricted T cell therapies. Among the most advanced immune targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on solid tumors, and NY-ESO-1 expressed by a majority of synovial sarcomas, but several other molecules reviewed here also have properties which suggest that they too could serve as effective targets for immunotherapy of childhood cancer.

Original languageEnglish (US)
Article number00003
JournalFrontiers in Oncology
Volume2
Issue numberJAN
DOIs
StatePublished - 2012
Externally publishedYes

Keywords

  • Adoptive immunotherapy
  • Antibody therapy
  • Chimeric antigen receptor
  • Immunotherapy
  • Pediatric cancer
  • Tumor antigens
  • Tumor immunity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Immunotherapy targets in pediatric cancer'. Together they form a unique fingerprint.

Cite this